Cargando…
Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
Background: Although combination immunotherapies incorporating local and systemic components have shown promising results in treating solid tumors, varied tumor microenvironments (TMEs) can impact immunotherapeutic efficacy. Method: We designed and evaluated treatment strategies for breast and pancr...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706583/ https://www.ncbi.nlm.nih.gov/pubmed/36451859 http://dx.doi.org/10.7150/thno.73218 |
_version_ | 1784840535995842560 |
---|---|
author | Wang, James Fite, Brett Z. Kare, Aris J. Wu, Bo Raie, Marina Tumbale, Spencer K. Zhang, Nisi Davis, Ryan R. Tepper, Clifford G. Aviran, Sharon Newman, Aaron M. King, Daniel A. Ferrara, Katherine W. |
author_facet | Wang, James Fite, Brett Z. Kare, Aris J. Wu, Bo Raie, Marina Tumbale, Spencer K. Zhang, Nisi Davis, Ryan R. Tepper, Clifford G. Aviran, Sharon Newman, Aaron M. King, Daniel A. Ferrara, Katherine W. |
author_sort | Wang, James |
collection | PubMed |
description | Background: Although combination immunotherapies incorporating local and systemic components have shown promising results in treating solid tumors, varied tumor microenvironments (TMEs) can impact immunotherapeutic efficacy. Method: We designed and evaluated treatment strategies for breast and pancreatic cancer combining magnetic resonance-guided focused ultrasound (MRgFUS) ablation and antibody therapies. With a combination of single-cell sequencing, spectral flow cytometry, and histological analyses, we profiled an immune-suppressed KPC (Kras(+/LSL-G12D); Trp53(+/LSL-R172H); Pdx1-Cre) pancreatic adenocarcinoma (MT4) model and a dense epithelial neu deletion (NDL) HER2(+) mammary adenocarcinoma model with a greater fraction of lymphocytes, natural killer cells and activated dendritic cells. We then performed gene ontology analysis, spectral and digital cytometry to assess the immune response to combination immunotherapies and correlation with survival studies. Result: Based on gene ontology analysis, adding ablation to immunotherapy enriched immune cell migration pathways in the pancreatic cancer model and extensively enriched wound healing pathways in the breast cancer model. With CIBERSORTx digital cytometry, aCD40 + aPD-1 immunotherapy combinations enhanced dendritic cell activation in both models. In the MT4 TME, adding the combination of aCD40 antibody and checkpoint inhibitors (aPD-1 and aCTLA-4) with ablation was synergistic, increasing activated natural killer cells and T cells in distant tumors. Furthermore, ablation with immunotherapy upregulated critical Ly6c myeloid remodeling phenotypes that enhance T-cell effector function and increased granzyme and protease encoding genes by as much as 100-fold. Ablation combined with immunotherapy then extended survival in the MT4 model to a greater extent than immunotherapy alone. Conclusion: In summary, TME profiling informed a successful multicomponent treatment protocol incorporating ablation and facilitated differentiation of TMEs in which ablation is most effective. |
format | Online Article Text |
id | pubmed-9706583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-97065832022-11-29 Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer Wang, James Fite, Brett Z. Kare, Aris J. Wu, Bo Raie, Marina Tumbale, Spencer K. Zhang, Nisi Davis, Ryan R. Tepper, Clifford G. Aviran, Sharon Newman, Aaron M. King, Daniel A. Ferrara, Katherine W. Theranostics Research Paper Background: Although combination immunotherapies incorporating local and systemic components have shown promising results in treating solid tumors, varied tumor microenvironments (TMEs) can impact immunotherapeutic efficacy. Method: We designed and evaluated treatment strategies for breast and pancreatic cancer combining magnetic resonance-guided focused ultrasound (MRgFUS) ablation and antibody therapies. With a combination of single-cell sequencing, spectral flow cytometry, and histological analyses, we profiled an immune-suppressed KPC (Kras(+/LSL-G12D); Trp53(+/LSL-R172H); Pdx1-Cre) pancreatic adenocarcinoma (MT4) model and a dense epithelial neu deletion (NDL) HER2(+) mammary adenocarcinoma model with a greater fraction of lymphocytes, natural killer cells and activated dendritic cells. We then performed gene ontology analysis, spectral and digital cytometry to assess the immune response to combination immunotherapies and correlation with survival studies. Result: Based on gene ontology analysis, adding ablation to immunotherapy enriched immune cell migration pathways in the pancreatic cancer model and extensively enriched wound healing pathways in the breast cancer model. With CIBERSORTx digital cytometry, aCD40 + aPD-1 immunotherapy combinations enhanced dendritic cell activation in both models. In the MT4 TME, adding the combination of aCD40 antibody and checkpoint inhibitors (aPD-1 and aCTLA-4) with ablation was synergistic, increasing activated natural killer cells and T cells in distant tumors. Furthermore, ablation with immunotherapy upregulated critical Ly6c myeloid remodeling phenotypes that enhance T-cell effector function and increased granzyme and protease encoding genes by as much as 100-fold. Ablation combined with immunotherapy then extended survival in the MT4 model to a greater extent than immunotherapy alone. Conclusion: In summary, TME profiling informed a successful multicomponent treatment protocol incorporating ablation and facilitated differentiation of TMEs in which ablation is most effective. Ivyspring International Publisher 2022-11-14 /pmc/articles/PMC9706583/ /pubmed/36451859 http://dx.doi.org/10.7150/thno.73218 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wang, James Fite, Brett Z. Kare, Aris J. Wu, Bo Raie, Marina Tumbale, Spencer K. Zhang, Nisi Davis, Ryan R. Tepper, Clifford G. Aviran, Sharon Newman, Aaron M. King, Daniel A. Ferrara, Katherine W. Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
title | Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
title_full | Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
title_fullStr | Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
title_full_unstemmed | Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
title_short | Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
title_sort | multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706583/ https://www.ncbi.nlm.nih.gov/pubmed/36451859 http://dx.doi.org/10.7150/thno.73218 |
work_keys_str_mv | AT wangjames multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT fitebrettz multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT karearisj multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT wubo multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT raiemarina multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT tumbalespencerk multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT zhangnisi multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT davisryanr multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT teppercliffordg multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT aviransharon multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT newmanaaronm multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT kingdaniela multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer AT ferrarakatherinew multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer |